Foxall P J, Singer J M, Hartley J M, Neild G H, Lapsley M, Nicholson J K, Souhami R L
Institute of Urology and Nephrology, University College London Medical School, University of London, London, United Kingdom.
Clin Cancer Res. 1997 Sep;3(9):1507-18.
Ifosfamide is an oxazophosphorine widely used in the treatment of cancer in children and adults. Nephrotoxicity and neurotoxicity are major side effects. The aim of this study was to use high-resolution proton nuclear magnetic resonance (1H NMR) spectroscopy of urine to identify novel biochemical markers of ifosfamide-induced toxicity. Urine samples were collected from 10 nonencephalopathic patients (who had not previously received nephrotoxic chemotherapy) immediately prior to the first ifosfamide dose and at timed intervals for up to four treatment cycles. The findings were compared with those for urine samples collected from five patients during acute encephalopathic episodes. 1H NMR urinalysis identified a series of characteristic time-related changes in the excretion profiles of low molecular weight endogenous metabolites during ifosfamide therapy. These changes included a decreased excretion of hippurate and an increased excretion of glycine, histidine, glucose, lactate, and trimethylamine-N-oxide. Two nonencephalopathic patients had marked but transient glutaric or adipic aciduria during the second cycle of ifosfamide treatment. Urinary retinol-binding protein rose acutely after each treatment cycle but usually returned to baseline levels. Maximum renal toxicity was observed by the fourth treatment cycle. The ratio of the urinary excretion of the uroprotectant mesna (active form) to dimesna (inactive form) correlated with the degree of renal toxicity. For the encephalopathic patients, the ifosfamide-induced changes in the urinary low molecular weight metabolite profile were similar to those for the nonencephalopathic group. In contrast to previous reports, none of the encephalopathic group developed glutaric aciduria, and i.v. methylene blue did not reverse neurotoxicity in the two patients who received it. The results suggest that ifosfamide nephrotoxicity involves both cortical and medullary regions of the nephron and that the urinary mesna:dimesna ratio may be important in assessing the degree of cytoprotection. This study demonstrates that 1H NMR can provide novel biochemical information on ifosfamide-induced toxicity and will be of value in the optimization of ifosfamide therapy.
异环磷酰胺是一种广泛用于治疗儿童和成人癌症的氧氮磷杂环化合物。肾毒性和神经毒性是其主要副作用。本研究的目的是利用尿液的高分辨率质子核磁共振(1H NMR)光谱来识别异环磷酰胺诱导毒性的新型生化标志物。在首次给予异环磷酰胺剂量之前以及在长达四个治疗周期的时间间隔内,从10名无脑病患者(此前未接受过肾毒性化疗)中采集尿液样本。将这些结果与在急性脑病发作期间从5名患者采集的尿液样本的结果进行比较。1H NMR尿液分析确定了异环磷酰胺治疗期间低分子量内源性代谢物排泄谱中一系列与时间相关的特征性变化。这些变化包括马尿酸盐排泄减少以及甘氨酸、组氨酸、葡萄糖、乳酸和氧化三甲胺排泄增加。两名无脑病患者在异环磷酰胺治疗的第二个周期出现明显但短暂的戊二酸或己二酸尿。每次治疗周期后尿视黄醇结合蛋白急剧上升,但通常会恢复到基线水平。在第四个治疗周期观察到最大肾毒性。尿路保护剂美司钠(活性形式)与地美司钠(非活性形式)的尿排泄率与肾毒性程度相关。对于脑病患者,异环磷酰胺引起的尿低分子量代谢物谱变化与无脑病组相似。与先前的报道相反,脑病组中没有患者出现戊二酸尿,并且静脉注射亚甲蓝并未使接受该药物的两名患者的神经毒性逆转。结果表明,异环磷酰胺肾毒性涉及肾单位的皮质和髓质区域,并且尿美司钠:地美司钠比率在评估细胞保护程度方面可能很重要。本研究表明,1H NMR可以提供有关异环磷酰胺诱导毒性的新型生化信息,并且在优化异环磷酰胺治疗方面将具有价值。